Atul A Deodhar1, Anand Kumthekar, Maureen Dubreuil. 1. aOregon Health & Science University, Portland, Oregon bBoston University School of Medicine cVA Boston Healthcare System, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition with articular and extra-articular manifestations. Remission, a state of absence of clinical and imaging signs of disease activity over time, is the goal of management. This review addresses the concept of minimal disease activity (MDA) in axSpA, which is less stringent than remission, and is closer to patient and provider acceptable low disease state. RECENT FINDINGS: Existing axSpA treatments improve physical function and quality of life, and lead to remission in a minority of patients. A consistent MDA state decreases disease progression in rheumatoid arthritis and psoriatic arthritis. We argue a need to develop MDA in axSpA for clinical practice and clinical trials and propose methodology. Considering that MDA will be used in clinical practice, its elements must be easy to collect and cover both musculoskeletal and extra-articular domains. MDA will complement current disease activity measures in axSpA. SUMMARY: Defining an MDA target in axSpA would provide an outcome measure that is less stringent than remission, and will likely predict function and quality of life. We propose methods to develop MDA in axSpA and that further research be performed to determine if treating to an MDA target in axSpA improves patient outcomes.
PURPOSE OF REVIEW: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition with articular and extra-articular manifestations. Remission, a state of absence of clinical and imaging signs of disease activity over time, is the goal of management. This review addresses the concept of minimal disease activity (MDA) in axSpA, which is less stringent than remission, and is closer to patient and provider acceptable low disease state. RECENT FINDINGS: Existing axSpA treatments improve physical function and quality of life, and lead to remission in a minority of patients. A consistent MDA state decreases disease progression in rheumatoid arthritis and psoriatic arthritis. We argue a need to develop MDA in axSpA for clinical practice and clinical trials and propose methodology. Considering that MDA will be used in clinical practice, its elements must be easy to collect and cover both musculoskeletal and extra-articular domains. MDA will complement current disease activity measures in axSpA. SUMMARY: Defining an MDA target in axSpA would provide an outcome measure that is less stringent than remission, and will likely predict function and quality of life. We propose methods to develop MDA in axSpA and that further research be performed to determine if treating to an MDA target in axSpA improves patient outcomes.
Authors: George A Wells; Maarten Boers; Beverley Shea; Peter M Brooks; Lee S Simon; C Vibeke Strand; Daniel Aletaha; Jennifer J Anderson; Claire Bombardier; Maxime Dougados; Paul Emery; David T Felson; Jaap Fransen; Dan E Furst; Johanna M W Hazes; Kent R Johnson; John R Kirwan; Robert B M Landewé; Marissa N D Lassere; Kaleb Michaud; Maria Suarez-Almazor; Alan J Silman; Josef S Smolen; Desiree M F M Van der Heijde; Piet L C M van Riel; Fred Wolfe; Peter S Tugwell Journal: J Rheumatol Date: 2005-10 Impact factor: 4.666
Authors: Sofia Ramiro; Désirée van der Heijde; Astrid van Tubergen; Carmen Stolwijk; Maxime Dougados; Filip van den Bosch; Robert Landewé Journal: Ann Rheum Dis Date: 2014-05-07 Impact factor: 19.103
Authors: G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel Journal: Ann Rheum Dis Date: 2008-05-19 Impact factor: 19.103